Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
Sümeyye KoçKerim AslanYüksel TerziFerah KızılaySerkan DemirDürdane Bekar AksoyFatma KurtuluşNuray BilgeEgemen IdimanCihat UzunköprüSerdal GüngörVedat CilingirEthemoglu OzlemCavit BozHaluk GümüşAhmet Kasim KilicAyşın Kısabay AkLevent Sinan BirÖmer Faruk TuranSoysa AysunMesrure KöseoğluGülnur Tekgöl UzunerHasan BayındırCanbaz Kabay SibelMustafa ÇamVildan YaylaHüseyin TanAbdülcemal ÖzcanÖzlem TaşkapıoğluMuammer KorkmazYusuf TamamYılmaz İnançHüsnü EfendiDilcan KotanMehmet Fatih YetkinAdnan Burak BilgiçHikmet SaçmaciSerpil DemirciYahya ÇelikTuran PoyrazMurat TerziPublished in: Balkan medical journal (2024)
For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.